Experimental Stem Cell Therapy For Parkinson's Shows Promise in Phase I Trial: Reuters
Portfolio Pulse from Benzinga Newsbot
Bayer's subsidiary BlueRock has reported initial success in a Phase I trial for an experimental stem cell therapy for Parkinson's disease. The therapy was well-tolerated and the transplanted cells grew as intended in the patients' brains. This success has led Bayer to advance to the second stage of testing on humans, with patient enrolment expected in the first half of 2024.
June 28, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bayer's subsidiary BlueRock's success in Phase I trial for a stem cell therapy for Parkinson's disease could potentially boost Bayer's stock in the short term.
The success of the Phase I trial is a significant milestone for Bayer and its subsidiary BlueRock. This could potentially attract more investors, leading to a rise in Bayer's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100